The accurate classification of non-small cell lung carcinoma (NSCLC) into lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) is essential for both clinical practice and lung cancer research. Although the standard WHO diagnosis of NSCLC on biopsy material is rapid and economic, more than 13% of NSCLC tumors in the USA are not further classified. The purpose of this study was to analyze the genome-wide pattern differences in copy number variations (CNVs) and to develop a CNV signature as an adjunct test for the routine histopathologic classification of NSCLCs. We investigated the genome-wide CNV differences between these two tumor types using three independent patient datasets. Approximately half of the genes examined exhibited sig- Of greater importance, the significant differences between these tumors may offer the possibility of identifying the origin of tumors whose origin is unknown.
| I N T R O D U C T I O N
Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) are the two major histological types of non-small cell lung cancer (NSCLC), constituting 54% and 28% of NSCLC, respectively (http://seer.cancer.gov/). Considering that large cell cancer (LCC) samples are undifferentiated NSCLCs that do not show morphologic or immunostaining evidence of glandular or squamous differentiation, 1, 2 these two subtypes cover over 90% of NSCLC cases in the USA.
One of the first clinical diagnostic tasks is to distinguish between NSCLC and SCLC. 3 However, recent advances, especially in personalized medicine and inclusion in clinical trials, have made it imperative to distinguish LUAD from LUSC. [4] [5] [6] The current recommended WHO methodology for this separation, which is based on routine H&E examination combined with immunostaining, is rapid, accurate, and economic. 7 However, most NSCLC tumors (70%) are currently diagnosed from small biopsies or cytology specimens, which greatly increases the difficulties of accurate classification, even with the use of immunostaining. [6] [7] [8] [9] More importantly, the agreement between expert lung cancer pathologists on the diagnosis of poorly differentiated NSCLC is modest. 8, 9 According to the SEER database, a National Cancer Institute initiative that provides information on cancer statistics in the USA, more than 13% of NSCLC tumors (amounting to an estimated 23 971 cases per year in the USA) are not further classified (https:// seer.cancer.gov/csr/1975_2013/browse_csr.php?sectionSEL 5 15&page SEL 5 sect_15_table. 28 .html) and are usually referred to as NSCLC-NOS (not otherwise specified) 9, 10 . Such patients may not receive optimal therapy or become included in a clinical trial for specific types of NSCLC. All of these facts point to the value of molecular classifications as nonsubjective adjuvant methods. These methods include digital nuclear imaging, mutation analysis, mRNA expression values and various other molecular methods, either alone or in combination. [10] [11] [12] [13] [14] [15] [16] As several papers have addressed copy number variation (CNV) patterns in NSCLC, a gain in corresponding knowledge is incremental. 17, 18 However, a comprehensive analysis across independent datasets and associations with other parameters, such as known driver genes in lung adenocarcinoma (e.g., mutEGFR), is warranted. The CNVs between LUADs and LUSCs are genome-wide and of wide deflection. 19 Some CNVs are present in both types, whereas other CNVs are tumor-specific. 1 Previous studies have shown that CNVs play important roles in histologic classifications of NSCLC. 20, 21 More importantly, DNA-based tests are more robust when applied to formalin-fixed paraffin-embedded tissues. Therefore, we aimed to use the global patterns of CNVs as a method to subclassify NSCLC, especially the poorly differentiated cases of NSCLC.
The purposes of our study were as follows: (1) to investigate and document the genome-wide CNV differences between these two tumor types, (2) to develop a molecular classifier and to identify signature genes of NSCLC based on the differences in CNVs, and (3) to compare the CNV patterns of LUADs and LUSCs to those of tumors with similar histology arising in other major organs.
| MATERIALS A ND METHODS
Three independent datasets were used in this study. The Cancer Genome Atlas (TCGA) dataset was downloaded through the public TCGA Data Portal (https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp). Table S2 summarizes these three datasets. As the TCGA dataset has the largest sample size and includes many nonmalignant samples, this dataset was used to train the classification (supervised pattern recognition) model and to identify the signature genes.
The SPORE and EDRN/Canary datasets were used for validation.
Because level 3 TCGA CNV values were log 2 (copy number/2)-transformed, the SPORE and EDRN/Canary CNV values were processed in the same manner. All data were normalized by Z-score transformation.
We first investigated the global differences of CNV patterns between LUAD and LUSC tumor samples. The CNVs were further compared between LUSC and LUAD samples by a two-tailed t-test.
Bonferroni correction was used as a way to control for the family-wise error rate. Since this analysis was limited only to the TCGA dataset, all 23 494 genes were considered.
Next, we compared the CNV differences between LUAD or LUSC and the following related major cancer types: head and neck carcinoma (HNSC), esophageal squamous cell carcinoma (ESSC), colorectal carcinoma (CRCA), breast carcinoma (BRCA), ovarian serous cystadenocarcinoma (OV), and prostate adenocarcinoma (PRAD). All CNV data regarding these cancer types were downloaded from the public TCGA dataset and were preprocessed in the same manner as the LUAD and LUSC data.
To overcome the inherent noise of the microarray data and the complicated multi-relationships among genes and to select potential signature genes that distinguish LUADs from LUSCs out of approximately 20 000 genes, an algorithm integrating elastic net (EN), 22 partial least squares (PLS), 23 and naive bayes (NB) 24 was applied to complement the advantages of each method. Each method is briefly summarized in the Supporting Information. The integrated EN-PLS-NB algorithm is described in detail in the Supporting Information with the corresponding flowchart in Supporting Information Figure   S1A .
The procedure used to identify signature genes classifying LUADs and LUSCs is described below with the corresponding flowchart in Supporting Information Figure S1B . We first applied the EN-PLS-NB algorithm to the TCGA lung cancer dataset consisting of 496 LUAD samples and 490 LUSC samples with 18 819 overlapping genes to obtain a raw list of signature genes, which we termed the "statistically selected gene list."
To avoid the known important genes from being buried with thousands of whole-genome genes, 11 previously proven tumor-associated genes of NSCLC were identified by a literature review (Supporting Information After the training procedure using LUADs and LUSCs of the TCGA dataset, the final classification model with the signature gene set was validated on three independent datasets (see Supporting Information Table S2 ). Using only CNV values of the same signature genes, we first validated whether the classifier could separate tumors from corresponding non-malignant tissues in the TCGA dataset; second, we validated whether it could separate the tumor types in the SPORE dataset;
and third, we examined its sensitivity in the EDRN/Canary dataset consisting of only LUAD samples. The SPORE dataset was measured by a completely different platform from those of the TCGA and EDRN/ Canary datasets.
All analyses were performed using MATLAB codes, which are available upon request. We are currently working on the online running edition (https://clickgwas.org).
| R E S U LTS
3.1 | Genome-wide CNV differences between LUAD and LUSC Table S3 ).
According to the TCGA annotation ( Figure 1 and Table 1 ), four p arms (chromosomes 13, 14, 15, and 22) contain no listed genes, and 21p
contains only six genes. Of the remaining 39 somatic chromosomal arms, 33 (84.6%) had significant CNV differences between LUAD and LUSC, ranging from 1% to 100% (mean 5 45.6%). Of the two NSCLC types, LUSC tumors showed more deflections (either gains or losses) compared with the corresponding non-malignant samples, involving 32.1% of the genes, while LUAD only showed 15.2% of genes deflected. LUSC tumors also showed the greatest deflections for gain (chromosome arms 2p, 12p, and part of 22q) and loss (3p, 4p, and 5q). For LUADs, the greatest longsegment deflections involved losses on parts of 6q, 15q, 19p, and 22q.
The most striking changes (for both percentages of involved genes and amplitude of the changes) were observed on chromosome 3, with 100% gains on 3q in LUSC, confirming previously reported findings. 18, [25] [26] [27] In contrast to 3q gains in LUSC, a loss of most or all of 3p characterized both LUAD and LUSC, being more prominent in LUSC ( Figure 1 ). Losses of 3p were the first cytogenetic alteration found in lung cancers, occurring early during lung cancer pathogenesis, and multiple tumor suppressor genes are located in this region. [28] [29] [30] Long segmental gains at 5p were characteristic of both LUAD and LUSC (more so in LUAD) and involved the telomerase reverse transcriptase gene TERT (5p15). Chromosome 7, the location of Met (7q.31), is the only chromosome that showed gains of almost all contained genes on both arms for both LUSCs and LUADs ( Figure 1 ). Chromosome 22 showed gains of almost all contained genes for LUSCs and a small loss for LUADs ( Figure 1 ).
In addition to large segment gains, short segment gains (amplicons)
were also present. LUADs were characterized by narrow region gains KRAS is located in a region of long segment gain involving all of 12p that is characteristic of LUSC.
Narrow band regions of loss (deletions) were fewer than narrow band regions of gain, and the most prominent one was at 9p21 (Supporting Information Figure S3 ). This deleted region contains CDKN2A
(also known as p16) and related genes, namely CDKN2B and MTAP.
CDKN2A inactivation is more common in LUSC, 31 and homozygous deletions are more common in LUSC (20.2%) than in LUAD (11.9%).
Both LUSC and LUAD tumors had approximately equal frequencies of gains for the MDM2 gene (16.5% and 19.2%, respectively), consistent with previous reports 32, 33 (see Supporting Information Figure S4 ).
Supporting Information Table S2 summarizes 11 known important lung tumor-associated genes that were identified by a literature review.
Four of them-PIK3CA, SOX2, FGFR1 (for LUSCs), and NKX2-1 (for LUADs)-are significantly different in LUAD and LUSC samples according to the t-test with Bonferroni correction (P-value < 2.10E-6). The top two genes (PIK3CA and SOX2) were selected for inclusion in the final 33 signature genes (see Table 2 ).
3.2 | Identifying CNV signature genes to distinguish LUAD from LUSC and to distinguish tumors from their corresponding non-malignant samples to the classification model in descending order in Table 2 
34-38
Twenty-six of the signature genes have greater deflections for LUSC tumors, whereas seven have greater deflections for LUAD tumors (highlighted in yellow in Table 2 ). There are 21 genes located on 3q, the site of the greatest deflection for LUSCs. Others are located on 4p, 6q, 8p, 9p, 15q, and 19. LUADs with a sensitivity of 0.96 (Table 3 ). The SPORE data were achieved with platforms that are different from the one used for the TCGA dataset. These results strongly confirm that our classifier possesses high classification performance regardless of the data platform used.
We further investigated whether we could reduce the number of signature genes without considerably decreasing the accuracy of our Supporting Information Figure S5 shows the genome-wide CNV t-test results between LUAD and CRCA/BRCA/PRAD/OV tumor samples in the TCGA dataset. Supporting Information Figure S6 shows the genome-wide CNV t-test between LUSC and HNSC/ESSC tumor samples in the TCGA dataset. As shown in these figures and Supporting
Information Table S6 , in all comparisons except for LUSC from ESSC (only 2.9%), there were significant differences ranging from 42.5% to 55% of the genes after using Bonferroni-correction as the family-wise control.
As shown in Figure 3 , it is clear that, except for chromosome 21, In Supporting Information Figure S7 , FADD shows a very impressive narrow amplicon on 11q13.3 that is only in ESSC, while no published research mentions the relationship between them, even though it has already been proven to play an important role in LUSC and HNSC. 41, 42 Of the FGF members, FGF19 is located at 11q13.3. FGF19 overexpression has been implicated in the pathogenesis of some cancers, especially in murine models of hepatocellular carcinoma. 43 We found only one reference to the role of FGF19 in lung cancer. 44 The 11q13 amplicon also contains the associated FGF genes FGF3 and FGF4 and has been reported to be present in other squamous carcinomas, including head and neck and esophageal carcinomas, 45 as well as breast cancers. 46 Of great interest, the 8p and 11q amplicons containing NKX2-1 (TTF-1) is the primary marker used to distinguish LUAD from LUSC. However, from Supporting Information Figure S8 , we can clearly see a large overlap between the expression value distributions in these two subgroups. Normally, the sensitivity of NKX2-1 (TTF-1) is approximately 80%. 50, 51 Supporting Information Figure S8 shows that the lower cutoff value will result in higher sensitivity but a higher FP (false positive) rate. We chose the cutoff value as 10.3 (log 2 -transformed). The corresponding sensitivity is 81%, and the corresponding FP is 5%, which means that 5% of LUSC cases would be falsely diagnosed as LUAD. Under the same considerations, we chose the cutoff value of NAPSA as 12.5 (log 2 -transformed). The corresponding sensitivity of LUAD is 81%, and the FP rate for LUSC is 16%. Supporting
Information Figure S8 also proves that it is impossible to distinguish LUAD from non-malignant samples using these two markers. However, Considering that a fraction of the TCGA diagnostic materials were of less-than-optimal quality (e.g., frozen sections instead of permanently fixed H&E slides) 9, 10 , and in spite of the partially subjective nature of pathologic diagnosis, these 15 samples require a further diagnosis. It is highly possible that these so-called LUAD and LUSC cases For the two most frequently mutated oncogenes in LUADs of the lung, that is, KRAS and EGFR, 3,52-55 we examined whether these mutations were associated with specific CNV alterations. Tumors with either one of these oncogenic changes failed to exhibit copy number changes that were significantly different from those of wild type tumors. There was no significant difference in CNVs for these 33 genes according to either gender or smoking history (data not shown). We also compared the performance of our 33-gene classifier with that of another CNV classifier proposed by Li et al. 14 In their study, the classifier consisting of 266 probes was not tested by an independent validation dataset. According to their results, it had a comparable accuracy to our classifier; however, its sensitivity was much lower (0.65).
Because different platforms were used to measure the CNV, only 26 of our 33 signature genes were included in Li's data, indicating that more than 20% of our signature genes were missing. Therefore, we could not use our signature genes and model to classify the data used by them.
In summary, we developed and validated an accurate CNV classi- 
